A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity

Activo, no reclutaFase 3ClinicalTrials.gov

ID: NCT06662383Tipo: INTERVENTIONALInicio: 1 de nov de 2024Fin estimado: 1 de dic de 2026

Traducción no disponible, mostrando original

Resumen

The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Have obesity and a history of at least one self-reported unsuccessful dietary effort to reduce body weight.

Criterios de exclusión

Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days before screening.
Have a prior or planned surgical treatment for obesity.
Have a prior or planned endoscopic procedure and/or device-based therapy for obesity.
Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening.
Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2).
Have had within the past 90 days before screening:
acute myocardial infarction
cerebrovascular accident (stroke)
coronary revascularization
hospitalization for unstable angina, or
hospitalization due to congestive heart failure.
Have New York Heart Association Functional Classification Class IV congestive heart failure.
Have a history of chronic or acute pancreatitis.

Intervenciones

drug

Retatrutide

Administered SC

drug

Tirzepatide

Administered SC

Ubicaciones

DIM Clínica Privada

Ramos Mejía, Buenos Aires, Argentina

Centro Médico Viamonte

Buenos Aires, Buenos Aires F.D., Argentina

Consultorio de Investigación Clínica EMO SRL

Buenos Aires, Buenos Aires F.D., Argentina

Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada

Buenos Aires, Buenos Aires F.D., Argentina

Centro de Investigaciones Metabólicas (CINME)

Buenos Aires, Argentina

Patrocinadores

PrincipalEli Lilly and Company

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Phase 3, Randomized, Double-Blind Study to Evaluate the... | EligiMed